PharmaSeq gets Phase I SBIR Grant for Microtransponder Cell-based Assays | GenomeWeb

NEW YORK, July 5 (GenomeWeb News) - PharmaSeq has received a Phase I SBIR grant form the National Cancer Institute to develop a multiplex cell assay on its microtransponder technology, the company said late last week.


Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.